Health Canada has authorized a new GLP-1 medication for weight loss that is taken as a daily pill rather than a weekly injection. Eli Lilly’s Foundayo is approved for adults with obesity, as well as for adults who are overweight and have at least one related medical problem such as high blood pressure or sleep apnea. The pill is also approved to help treat Type 2 diabetes.

Health Canada gave its authorization on November 13, and Eli Lilly spokesperson Ethan Pigott said the company expects the pill to be available in pharmacies in January. The approval gives Canadians who prefer not to use injections another option in a class of drugs that has changed how weight-loss treatment is delivered.

Eli Lilly already makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors linked to insulin production and hunger, GLP-1 and GIP. Its competitor Novo Nordisk manufactures the injectables Ozempic and Wegovy, which contain semaglutide, a drug that acts on GLP-1 receptors. Several other companies make generic semaglutide sold in Canada.

Foundayo’s active ingredient is orforglipron, a non-peptide GLP-1 receptor agonist. Because it is a smaller molecule than the peptides semaglutide and tirzepatide, orforglipron can be taken orally and absorbed without being broken down by the digestive system. Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with either Eli Lilly or Novo Nordisk, said the drug appears to be as effective as, if not more effective than, semaglutide and tirzepatide for weight loss.

Novo Nordisk already sells a GLP-1 pill in Canada, Rybelsus, but it is approved only for managing Type 2 diabetes and not for weight loss. The Wegovy pill, a weight-loss version made from semaglutide, is also expected to reach the Canadian market, but it is still awaiting Health Canada approval. Both Foundayo and the Wegovy pill are already approved and available in the United States.

Novo Nordisk has made semaglutide into a pill by adding an ingredient called salcaprozate sodium, or SNAC, which protects the drug from being broken down by digestive enzymes. Once swallowed, SNAC temporarily makes the area around it less acidic and helps the drug pass through the stomach lining into the bloodstream, Novo Nordisk spokesperson Kate Hanna said in an email.

The most common side effects of GLP-1 medications, whether injected or taken orally, are gastrointestinal, such as nausea and vomiting. Dr. Ur said whether he would prescribe Foundayo depends on the patient. He is still waiting for clinical trial results on whether orforglipron offers a cardiovascular benefit similar to that seen with semaglutide and tirzepatide.

Experts say GLP-1 medications should be used together with diet and exercise for weight loss. Some patients may prefer a pill to an injection, and the approval of Foundayo gives them a new choice once it reaches pharmacies.

36Views